A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.

A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.

Item
http://www.wikidata.org/entity/Q49153461
Striving for optimal bronchodilation: focus on olodaterolDifferential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterolPharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPDEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.
P2860

A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.

Item
http://www.wikidata.org/entity/Q49153461
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@en
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@nl
type
label
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@en
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@nl
prefLabel
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@en
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@en
P2093
P304
P31
P356
10.1016/J.RMED.2015.02.005
P433
P478
P577
P5875
P698
P921